M. Moscovici

发表

Sorafenib in advanced hepatocellular carcinoma.

Dieter Häussinger, Sergio Ricci, Armando Santoro, 2008, The New England journal of medicine.

Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses.

V. Mazzaferro, J. Bruix, M. Sherman, 2012, Journal of hepatology.

Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis.

D. Amadori, S. Ricci, G. Abou-Alfa, 2011, Gastrointestinal cancer research : GCR.

42 Phase II study of BAY 43-9006 in patients with advanced hepatocellular carcinoma (HCC)

D. Amadori, S. Ricci, G. Abou-Alfa, 2004 .

Efficacy and safety of sorafenib in patients with alcohol-related hepatocellular carcinoma: A sub-analysis from the SHARP trial

C. Porta, J. Bruix, J. Llovet, 2008 .

Is sorafenib (S) safe and effective in patients (pts) with hepatocellular carcinoma (HCC) and Child-Pugh B (CPB) cirrhosis?

D. Amadori, S. Ricci, G. Abou-Alfa, 2008 .

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma and vascular invasion or extrahepatic spread: A subanalysis from the SHARP trial

D. Amadori, V. Mazzaferro, J. Bruix, 2008 .

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to ECOG performance status: A subanalysis from the SHARP trial

J. Marrero, J. Bruix, J. Llovet, 2008 .

3507 ORAL Sorafenib improves survival in a large multi-center, randomized, placebo-controlled phase III trial in patients with hepatocellular carcinoma

V. Mazzaferro, S. Ricci, J. Llovet, 2007 .

Chemotherapies and targeted therapies in advanced hepatocellular carcinoma: from laboratory to clinic.

M. Moscovici, M. Neuman, M. Voiculescu, 2008, Journal of gastrointestinal and liver diseases : JGLD.

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.

C. Porta, V. Mazzaferro, J. Marrero, 2012, Journal of hepatology.

Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.

D. Amadori, L. Schwartz, S. Ricci, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

994 EFFICACY AND SAFETY OF SORAFENIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA AND PRIOR ANTI-TUMOR THERAPY: A SUBANALYSIS FROM THE SHARP TRIAL

J. Marrero, J. Bruix, P. Galle, 2008 .

An uncontrolled phase II study evaluating anti-tumor efficacy and safety of ortataxel (BAY 59-8862) in patients with taxane-resistant non-small cell lung cancer.

J. von Pawel, D. Voliotis, M. Moscovici, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and safety of sorafenib (Sor) in patients (Pts) with advanced hepatocellular carcinoma (HCC): Subgroup analyses of the SHARP trial by baseline (BL) transaminase (ALT/AST)/α-fetoprotein (AFP) and bilirubin (bil) levels.

J. Bruix, M. Sherman, J. Llovet, 2010 .

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma : Subanalyses of a phase III trial q , qq

C. Porta, V. Mazzaferro, J. Marrero, 2012 .